Aurobindo Pharma To Make And Sell COVAXX’s Covid-19 Vaccine for India, UNICEF


    Aurobindo Pharma Ltd on Thursday said it would make and sell US-based COVAXX’s Covid-19 vaccine candidate for supply in India and to the United Nations Children’s Fund (UNICEF) under a licensing deal.

    The Indian pharmaceutical company also has non-exclusive rights to sell the shot, which is currently undergoing an early-stage trial, in certain other emerging markets, the Hyderabad-based company said in an exchange filing.

    COVAXX, a unit of privately-owned United Biomedical Inc, plans to pursue mid- and late-stage trials for the vaccine candidate from early 2021 in Asia, Latin America and the US.

    The companies said the shot uses normal refrigeration as opposed to the freezing temperatures required for some vaccines, seen as beneficial for developing countries.

    Shares of Aurobindo Pharma rose 0.75 per cent and was trading at ₹ 896.55 at 13.47 pm on the Bombay Stock Exchange.

    Aurobindo said it could currently make 220 million doses, but is ramping up its facilities to reach a capacity of nearly 480 million by June 2021.